Lamivudine monotherapy for chronic hepatitis b infection with acute exacerbation revisited

European Journal of Gastroenterology and Hepatology

Volumn 21, Issue 4, 2009, Pages 357-361

  Sheu, Ming Jen ^a   Kuo, Hsing Tao ^a   Lin, Ching Yih ^a   Koay, Lok Beng ^a   Lee, Chuan ^a   Chen, Jyh Jou ^a   Tang, Ling Yu ^a   Tsai, Sun Lung ^a  

^a CHI MEI MEDICAL CENTER   (Taiwan)

Author keywords

Chronic hepatitis B; Genotype; Hepatitis B virus; Keywordsacute exacerbation; Lamivudine therapy; Sustained remission

Indexed keywords

HEPATITIS E ANTIGEN; LAMIVUDINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFICACY; FEMALE; GENOTYPE; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; REMISSION; TREATMENT DURATION; TREATMENT RESPONSE;

ACUTE DISEASE; ADULT; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPATITIS A VIRUS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; REMISSION INDUCTION; YOUNG ADULT;

EID: 67649609950     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3283131389     Document Type: Article

References (48)

1. Chen DS. From hepatitis to hepatoma: lessons from type B viral hepatitis. Science 1993; 262:369-370.
2. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337:1733-1745.
3. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2001; 34:1225-1241.
4. Morens DM, Folkers GK, Fauci AS. The challenge of emerging and re-emerging infectious diseases. Nature 2004; 430:242-249.
5. Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004; 350:1118-1129.
6. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132:2557-2576.
7. Lindh M, Andersson AS, Gusdal A. Genotypes, nt 1858 variants and geographic origin of hepatitis B virus: large-scale analysis using a new genotyping method. J Infect Dis 1997; 175:1285-1293.
8. Stuyver L, De Gendt S, Van Geyt C, Zoulim F, Fried M, Schinazi RF, et al. A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. J Gen Virol 2000; 81:67-74.
9. Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000; 118:554-559.
10. Kao JH, Liu CJ, Chen DS. Hepatitis B viral genotypes and lamivudine resistance. J Hepatol 2002; 36:303-306.
11. Yuen MF, Wong DK, Sablon E, Yuan HJ, Sum SM, Hui CK, et al. Hepatitis B virus genotype B and C do not affect the antiviral response to lamivudine. Antiviral Ther 2003; 8:531-534.
12. Buti M, Elefsiniotis I, Jardi R, Vargas V, Rodriguez-Frias F, Schapper M, et al. Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients. J Hepatol 2007; 47:366-372.
13. Liaw YF. Results of lamivudine trials in Asia. J Hepatol 2003; 39:S111-S115.
14. Chang TT, Lai CL, Chien RN, Guan R, Lim SG, Lee CM, et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2004; 19:1276-1284.
15. Liaw YF. Hepatitis flares and hepatitis B e antigen seroconversion: implication in anti-hepatitis B virus therapy. J Gastroenterol Hepatol 2003; 18:246-252.
16. Liaw YF, Chu CM, Su IJ, Huang MJ, Lin DY, Chang-Chien CS. Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis. Gastroenterology 1983; 84:216-219.
17. Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000; 119:172-180.
18. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001; 33:1527-1532.
19. Kumar M, Satapathy S, Monga R, Das K, Hissar S, Pande C, et al. A randomized controlled trial of lamivudine to treat acute hepatitis B. Hepatology 2007; 45:97-101.
20. Chen JJ, Lin CY, Sheu MJ, Kou HT, Sun CS, Tang LY, et al. Poor response to 18-month lamivudine monotherapy in chronic hepatitis B with Ig M anti-HBc and acute exacerbation. Aliment Pharmacol Ther 2006; 23:85-90.
21. Perrillo R. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001; 102:1009-1022.
22. Chien RN, Yeh CT, Tsai SL, Chu CM, Liaw YF. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology 2003; 38:1267-1273.
23. Hoofnagle JH, Shafritz DA, Popper H. Chronic type B hepatitis and the healthy HBsAg carrier state. Hepatology 1989; 7:758-763.
24. Liaw YF, Tsai SL. Pathogenesis and clinical significance of spontaneous exacerbations and remissions in chronic hepatitis B virus infection. Vir Hep Rev 1997; 3:143-154.
25. Greenberg HB, Pollard RB, Lutwick LI, Gregory PB, Robinson WS, Merigan TC. Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. N Engl J Med 1976; 295:517-522.
26. Desmyter J, De Groote J, Desmet VJ, Billiau A, Ray MB, Bradburne AF, et al. Administration of human fibroblast interferon in chronic hepatitis B infection. Lancet 1976; ii:645-647.
27. Sherman M, Shafran S, Burak K, Doucette K, Wong W, Girgrah N, et al. Management of chronic hepatitis B: consensus guidelines. Can J Gastroenterol 2007; 21 (Suppl C):5C-24C.
28. Hoofnagle JH, DiBisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997; 336:347-356.
29. Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC. Inhibition of the replication of hepatitis B virus in vitro by 2′, 3′-dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci U S A 1991; 88:8495-8499.
30. Jarvis B, Faulds D. Lamivudine: a review of its therapeutic potential in chronic hepatitis B. Drugs 1999; 58:101-141.
31. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 333:1657-1661.
32. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351:1521-1531.
33. Tuttleman JS, Pourcel C, Summers J. Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell 1986; 47:451-460.
34. Yokosuka O, Omata M, Imazeki F, Ito Y, Okuda K. Hepatitis B virus RNA transcripts and DNA in chronic liver disease. N Engl J Med 1986; 315:1187-1192.
35. Hussain M, Lok ASF. Mutations in the hepatitis B virus polymerase gene associated with antiviral treatment for hepatitis B. J Viral Hepat 1999; 6:183-194.
36. Chien RN, Lin CL, Liaw YF. The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B. J Hepatol 2003; 38:322-327.
37. Mahmood M, Mahmood M, Fariborz G, Hosein F, Hadi G, Zahra P, et al. Efficacy of lamivudine therapy on decompensated liver cirrhosis due to chronic hepatitis B. Hepatitis Monthly 2007; 7:77-81.
38. Marinos G, Naoumov NJ, Williams R. Impact of complete inhibition of viral replication on the cellular immune response in chronic hepatitis B virus infection. Hepatology 1996; 24:991-995.
39. Boni C, Bertoletti A, Penna A, Cavalli A, Pilli M, Urbani S, et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 1998; 102:968-975.
40. Hultgren C, Weiland O, Milich DR, Sällberg M. Cell-mediated immune responses and loss of hepatitis B e-antigen (HBeAg) during successful lamivudine and famciclovir combination therapy for chronic replicating hepatitis B virus infection. Clin Infect Dis 1999; 29:1575-1577.
41. Liaw YF, Tsai SL, Chien RN, Yeh CT, Chu CM. Prednisolone priming enhances Th1 response and efficacy of subsequent lamivudine therapy in patients with chronic hepatitis B. Hepatology 2000; 32:604-609.
42. Boni C, Penna A, Ogg GS, Bertoletti A, Pilli M, Cavallo C, et al. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 2001; 33:963-971.
43. Tsai SL, Sheen IS, Chien RN, Chu CM, Huang HC, Chuang YL, et al. Activation of Th1 immunity is a common immune mechanism for successful treatment of hepatitis B and C: tetramer assay and therapeutic implications. J Biomed Sci 2003; 10:120-135.
44. Lin CL, Tsai SL, Lee TH, Chien RN, Liao SK, Liaw YF. High frequency of functional anti-YMDD and -mutant cytotoxic T lymphocytes after in vitro expansion correlates with successful response to lamivudine therapy for chronic hepatitis B. Gut 2005; 54:152-161.
45. Tsai SL, Chen PJ, Lai MY, Yang PM, Sung JL, Huang JH, et al. Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. J Clin Invest 1992; 89:87-96.
46. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995; 13:29-60.
47. Lok ASF. Chronic hepatitis B. New Engl J Med 2002; 346:1682-1683.
48. Omata M. Treatment of chronic hepatitis B infection. N Engl J Med 1998; 339:114-115.